RxDoctor Payments Data

Tracy Edwards, MD

Family Medicine · Hiawassee, GANPI 1013979855

Payments from drug & device makers

$773in general payments, 2019–2025

Across 14 payments — averaging $55.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$392
  • Shockwave Medical, Inc$157
  • Bayer$112
  • Sunovion Pharmaceuticals Inc.$44
  • Cycle Pharmaceuticals Inc$22
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$16
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$75798%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen6$392
Shockwave Medical, Inc1$157
Bayer1$112
Sunovion Pharmaceuticals Inc.2$44
Cycle Pharmaceuticals Inc1$22
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$16
AstraZeneca1$15
Merck1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$773 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$265,505
Medicare patients
198
Services billed
3,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban149$127,444
TrulicityDulaglutide89$111,294
FarxigaDapagliflozin Propanediol73$61,786
JardianceEmpagliflozin67$36,688
XareltoRivaroxaban71$36,031
OzempicSemaglutide28$25,540
MyrbetriqMirabegron60$19,381
JanuviaSitagliptin Phosphate18$18,803
TradjentaLinagliptin27$13,443
LinzessLinaclotide12$12,482
Breo ElliptaFluticasone/Vilanterol28$11,752
InvokanaCanagliflozin26$8,922
Combivent RespimatIpratropium/Albuterol Sulfate13$6,547
Gabapentin230$4,246
Novolog FlexpenInsulin Aspart11$4,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$15$61,78673 claims
MerckJanuvia, Lagevrio (Eua)$15$21,65042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Hiawassee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →